Janet D. Sparks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Janet D. Sparks has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
Charles E. Sparks
Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA
37 shared publications- Harold C. Smith
OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA; University of Rochester, School of Medicine and Dentistry, Department of Biochemistry and Biophysics, 601 Elmwood Avenue, Rochester, NY 14642, USA
9 shared publications C E Sparks
Department of Pathology, University of Rochester, NY 14642, USA
8 shared publicationsJames P. Corsetti
8 shared publicationsJoanne Cianci
Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
8 shared publications- Chawnshang Chang
George Whipple Lab for Cancer Research, Departments of Pathology and Urology, and The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, USA
7 shared publications
Latest Publications
- Open Access
Non-Canonical Binding of a Small Molecule to Sortilin Alters Cellular Trafficking of ApoB and PCSK9 in Liver Derived Cells
Sortilin regulates hepatic exocytosis and endocytosis of ApoB containing lipoproteins (ApoB-Lp) and mediates the secretion of the subtilase PCSK9. To elucidate connections between these pathways, we previously identified a small molecule (cpd984) that binds to a non-canonical site on Sortilin. In hepatic cells cpd984 augments ApoB-Lp secretion, increases cellular PCSK9 levels, and reduces LDLR expression indicative of reduced secretion of PCSK9. We have shown that insulin-induced ApoB-Lp degradation occurs through Vps34-dependent autophagy. Here we show that the specific Vps34 inhibitor PIK-III enhances ApoB-100 secretion, reducing cellular levels of PCSK9 and Sortilin resulting in reduced LDLR expression, which implicates a role for autophagy in PCSK9 secretion. Results suggest that Sortilin is central to both PCSK9 and ApoB-100 secretion. Finally, we found that cpd984 in yeast blocks CPY secretion while increasing vacuolar homotypic fusion in a Vps10-dependent manner, indicating an evolutionarily conserved mechanism required for lysosomal protease trafficking.
Open AccessNon-Canonical Binding of a Small Molecule to Sortilin Alters Cellular Trafficking of ApoB and PCSK9 in Liver Derived Cells
Sortilin regulates hepatic exocytosis and endocytosis of ApoB containing lipoproteins (ApoB-Lp) and mediates the secretion of the subtilase PCSK9. To elucidate connections between these pathways, we previously identified a small molecule (cpd984) that binds to a non-canonical site on Sortilin. In hepatic cells cpd984 augments ApoB-Lp secretion, increases cellular PCSK9 levels, and reduces LDLR expression indicative of reduced secretion of PCSK9. We have shown that insulin-induced ApoB-Lp degradation occurs through Vps34-dependent autophagy. Here we show that the specific Vps34 inhibitor PIK-III enhances ApoB-100 secretion, reducing cellular levels of PCSK9 and Sortilin resulting in reduced LDLR expression, which implicates a role for autophagy in PCSK9 secretion. Results suggest that Sortilin is central to both PCSK9 and ApoB-100 secretion. Finally, we found that cpd984 in yeast blocks CPY secretion while increasing vacuolar homotypic fusion in a Vps10-dependent manner, indicating an evolutionarily conserved mechanism required for lysosomal protease trafficking.
- 1 August 2017
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 28 (4) , 383-384
Autophagy and hepatic steatosis
- 1 August 2017
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 28 (4) , 383-384
Autophagy and hepatic steatosis
- 1 October 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 479 (3) , 551-556
Phosphatidylinositol (3,4,5)-trisphosphate binds to sortilin and competes with neurotensin: Implications for very low density lipoprotein binding
- 1 October 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 479 (3) , 551-556
Phosphatidylinositol (3,4,5)-trisphosphate binds to sortilin and competes with neurotensin: Implications for very low density lipoprotein binding
- 2 August 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 478 (2) , 546-552
Sortilin facilitates VLDL-B100 secretion by insulin sensitive McArdle RH7777 cells
- 2 August 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 478 (2) , 546-552
Sortilin facilitates VLDL-B100 secretion by insulin sensitive McArdle RH7777 cells
- 1 December 2015
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 26 (6) , 598-600
The enigmatic role of sortilin in lipoprotein metabolism
- 1 December 2015
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 26 (6) , 598-600
The enigmatic role of sortilin in lipoprotein metabolism
- Open Access
- 23 November 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 469 (2) , 326-331
Insulin dependent apolipoprotein B degradation and phosphatidylinositide 3-kinase activation with microsomal translocation are restored in McArdle RH7777 cells following serum deprivation
- 23 November 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 469 (2) , 326-331
Open AccessInsulin dependent apolipoprotein B degradation and phosphatidylinositide 3-kinase activation with microsomal translocation are restored in McArdle RH7777 cells following serum deprivation
- 1 October 2015
- Published by Wolters Kluwer Health in Hypertension
- Vol. 66 (4) , 881-891
Androgen Receptor Promotes Abdominal Aortic Aneurysm Development via Modulating Inflammatory Interleukin-1α and Transforming Growth Factor-β1 Expression
Sex difference is a risk factor for abdominal aortic aneurysm (AAA) formation yet the reason for male predominance remains unclear. Androgen and the androgen receptor (AR) influence the male sex difference, indicating that AR signaling may affect AAA development. Using angiotensin II–induced AAA in apolipoprotein E null mouse models (82.4% AAA incidence), we found that mice lacking AR failed to develop AAA and aorta had dramatically reduced macrophages infiltration and intact elastic fibers. These findings suggested that AR expression in endothelial cells, macrophages, or smooth muscle cells might play a role in AAA development. Selective knockout of AR in each of these cell types further demonstrated that mice lacking AR in macrophages (20% AAA incidence) or smooth muscle cells (12.5% AAA incidence) but not in endothelial cells (71.4% AAA incidence) had suppressed AAA development. Mechanism dissection showed that AR functioned through modulation of interleukin-1α (IL-1α) and transforming growth factor-β1 signals and by targeting AR with the AR degradation enhancer ASC-J9 led to significant suppression of AAA development. These results demonstrate the underlying mechanism by which AR influences AAA development is through IL-1α and transforming growth factor-β1, and provides a potential new therapy to suppress/prevent AAA by targeting AR with ASC-J9.
- 1 October 2015
- Published by Wolters Kluwer Health in Hypertension
- Vol. 66 (4) , 881-891
Androgen Receptor Promotes Abdominal Aortic Aneurysm Development via Modulating Inflammatory Interleukin-1α and Transforming Growth Factor-β1 Expression
Sex difference is a risk factor for abdominal aortic aneurysm (AAA) formation yet the reason for male predominance remains unclear. Androgen and the androgen receptor (AR) influence the male sex difference, indicating that AR signaling may affect AAA development. Using angiotensin II–induced AAA in apolipoprotein E null mouse models (82.4% AAA incidence), we found that mice lacking AR failed to develop AAA and aorta had dramatically reduced macrophages infiltration and intact elastic fibers. These findings suggested that AR expression in endothelial cells, macrophages, or smooth muscle cells might play a role in AAA development. Selective knockout of AR in each of these cell types further demonstrated that mice lacking AR in macrophages (20% AAA incidence) or smooth muscle cells (12.5% AAA incidence) but not in endothelial cells (71.4% AAA incidence) had suppressed AAA development. Mechanism dissection showed that AR functioned through modulation of interleukin-1α (IL-1α) and transforming growth factor-β1 signals and by targeting AR with the AR degradation enhancer ASC-J9 led to significant suppression of AAA development. These results demonstrate the underlying mechanism by which AR influences AAA development is through IL-1α and transforming growth factor-β1, and provides a potential new therapy to suppress/prevent AAA by targeting AR with ASC-J9.
- Open Access
- 15 September 2014
- Published by American Diabetes Association in Diabetes
- Vol. 63 (10) , 3180-3188
Androgen Receptor Roles in Insulin Resistance and Obesity in Males: The Linkage of Androgen-Deprivation Therapy to Metabolic Syndrome
Prostate cancer (PCa) is one of the most frequently diagnosed malignancies in men. Androgen-deprivation therapy (ADT) is the first-line treatment and fundamental management for men with advanced PCa to suppress functions of androgen/androgen receptor (AR) signaling. ADT is effective at improving cancer symptoms and prolonging survival. However, epidemiological and clinical studies support the notion that testosterone deficiency in men leads to the development of metabolic syndrome that increases cardiovascular disease risk. The underlying mechanisms by which androgen/AR signaling regulates metabolic homeostasis in men are complex, and in this review, we discuss molecular mechanisms mediated by AR signaling that link ADT to metabolic syndrome. Results derived from various AR knockout mouse models reveal tissue-specific AR signaling that is involved in regulation of metabolism. These data suggest that steps be taken early to manage metabolic complications associated with PCa patients receiving ADT, which could be accomplished using tissue-selective modulation of AR signaling and by treatment with insulin-sensitizing agents.
- 15 September 2014
- Published by American Diabetes Association in Diabetes
- Vol. 63 (10) , 3180-3188
Open AccessAndrogen Receptor Roles in Insulin Resistance and Obesity in Males: The Linkage of Androgen-Deprivation Therapy to Metabolic Syndrome
Prostate cancer (PCa) is one of the most frequently diagnosed malignancies in men. Androgen-deprivation therapy (ADT) is the first-line treatment and fundamental management for men with advanced PCa to suppress functions of androgen/androgen receptor (AR) signaling. ADT is effective at improving cancer symptoms and prolonging survival. However, epidemiological and clinical studies support the notion that testosterone deficiency in men leads to the development of metabolic syndrome that increases cardiovascular disease risk. The underlying mechanisms by which androgen/AR signaling regulates metabolic homeostasis in men are complex, and in this review, we discuss molecular mechanisms mediated by AR signaling that link ADT to metabolic syndrome. Results derived from various AR knockout mouse models reveal tissue-specific AR signaling that is involved in regulation of metabolism. These data suggest that steps be taken early to manage metabolic complications associated with PCa patients receiving ADT, which could be accomplished using tissue-selective modulation of AR signaling and by treatment with insulin-sensitizing agents.
- 1 June 2014
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 25 (3) , 230-232
High-density lipoproteins
- 1 June 2014
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 25 (3) , 230-232
High-density lipoproteins
- 1 June 2014
- Published by Wolters Kluwer Health in Hypertension
- Vol. 63 (6) , 1345-1353
New Therapy via Targeting Androgen Receptor in Monocytes/Macrophages to Battle Atherosclerosis
The male sex has a higher risk to develop coronary artery diseases, including atherosclerosis. The androgen receptor (AR) is expressed in several atherosclerosis-associated cell types, including monocytes/macrophages, endothelial cells (ECs), and smooth muscle cells (SMCs), but its pathophysiological role in each cell type during the development of atherosclerotic lesions remains unclear. Using the Cre-loxP system, we selectively knocked out AR in these 3 cell types and the resultant AR knockout (ARKO) mice, monocyte/macrophage ARKO, EC-ARKO, and SMC-ARKO, were then crossed with the low-density lipoprotein receptor (LDLR) deficient (LDLR −/− ) mice to develop monocyte/macrophage ARKO-LDLR −/− , EC-ARKO-LDLR −/− , and SMC-ARKO-LDLR −/− mice for the study of atherosclerosis. The results showed that the monocyte/macrophage ARKO-LDLR −/− mice had reduced atherosclerosis compared with the wild-type-LDLR −/− control mice. However, no significant difference was detected in EC-ARKO-LDLR −/− and SMC-ARKO-LDLR −/− mice compared with wild-type-LDLR −/− mice, suggesting that the AR in monocytes/macrophages, and not in ECs and SMCs, plays a major role to promote atherosclerosis. Molecular mechanism dissection suggested that AR in monocytes/macrophages upregulated the tumor necrosis factor-α, integrin β2, and lectin-type oxidized LDL receptor 1 molecules that are involved in 3 major inflammation-related processes in atherosclerosis, including monocytes/macrophages migration and adhesion to human umbilical vein ECs, and subsequent foam cell formation. Targeting AR via the AR degradation enhancer, ASC-J9, in wild-type-LDLR −/− mice showed similar effects as seen in monocyte/macrophage ARKO-LDLR −/− mice with little influence on lipid profile. In conclusion, the AR in monocytes/macrophages plays key roles in atherosclerosis and targeting AR with ASC-J9 may represent a new potential therapeutic approach to battle atherosclerosis.
- 1 June 2014
- Published by Wolters Kluwer Health in Hypertension
- Vol. 63 (6) , 1345-1353
New Therapy via Targeting Androgen Receptor in Monocytes/Macrophages to Battle Atherosclerosis
The male sex has a higher risk to develop coronary artery diseases, including atherosclerosis. The androgen receptor (AR) is expressed in several atherosclerosis-associated cell types, including monocytes/macrophages, endothelial cells (ECs), and smooth muscle cells (SMCs), but its pathophysiological role in each cell type during the development of atherosclerotic lesions remains unclear. Using the Cre-loxP system, we selectively knocked out AR in these 3 cell types and the resultant AR knockout (ARKO) mice, monocyte/macrophage ARKO, EC-ARKO, and SMC-ARKO, were then crossed with the low-density lipoprotein receptor (LDLR) deficient (LDLR −/− ) mice to develop monocyte/macrophage ARKO-LDLR −/− , EC-ARKO-LDLR −/− , and SMC-ARKO-LDLR −/− mice for the study of atherosclerosis. The results showed that the monocyte/macrophage ARKO-LDLR −/− mice had reduced atherosclerosis compared with the wild-type-LDLR −/− control mice. However, no significant difference was detected in EC-ARKO-LDLR −/− and SMC-ARKO-LDLR −/− mice compared with wild-type-LDLR −/− mice, suggesting that the AR in monocytes/macrophages, and not in ECs and SMCs, plays a major role to promote atherosclerosis. Molecular mechanism dissection suggested that AR in monocytes/macrophages upregulated the tumor necrosis factor-α, integrin β2, and lectin-type oxidized LDL receptor 1 molecules that are involved in 3 major inflammation-related processes in atherosclerosis, including monocytes/macrophages migration and adhesion to human umbilical vein ECs, and subsequent foam cell formation. Targeting AR via the AR degradation enhancer, ASC-J9, in wild-type-LDLR −/− mice showed similar effects as seen in monocyte/macrophage ARKO-LDLR −/− mice with little influence on lipid profile. In conclusion, the AR in monocytes/macrophages plays key roles in atherosclerosis and targeting AR with ASC-J9 may represent a new potential therapeutic approach to battle atherosclerosis.